|
 |
| Lucentis
Offers New Hope to Patients with Macular
Degeneration |
Age-related
macular degeneration (AMD) is the leading
cause of severe central visual loss in people
over 50 years of age. Up until one year ago,
there was nothing available to slow-down this
devastating loss of vision. The revolutionary
new drug, Lucentis now offers this group of
patients hope for not only slowing down the
progression, but actually recovering vision
which has been lost.
|
|